WONDFO BIOTECH(SZ:300482)2022-12-06 08:40Group 1: Company Goals and Strategy - The company aims to achieve a revenue target of 10 billion in 10 years, based on strategic planning conducted by professional institutions [2] - To reach this target, the company needs to achieve an annual growth rate of 30%-40%, which requires expanding beyond current POCT products into IVD and medical device products [2] Group 2: Financial Performance and Market Impact - The gross margin for pregnancy test strips is lower due to increased sales proportion, while the overall gross margin is affected by declining prices of domestic pregnancy products [3] - The depreciation of the RMB positively impacts the company as export sales significantly exceed the increased costs of imported raw materials [3] Group 3: Market Coverage and Client Distribution - The company has approximately 15% market share in tertiary hospitals, with a focus on ICU and emergency departments [3] - Coverage in grassroots hospitals is around 20%, indicating a significant market presence [4] Group 4: Product Development and Innovation - The company plans to enhance product sensitivity through optimization of biological raw materials and microfluidic technology [4] - New products are expected to be launched in the US market, including low-sensitivity drug tests and tumor marker detection products [4] Group 5: Sales Strategy and Market Positioning - The company employs a deep marketing strategy for quantitative products, while qualitative products are sold through provincial agents [5] - The company is focused on maintaining gross margins by continuously launching new products and optimizing production costs [5] Group 6: International Market Challenges - The company faced challenges in the Americas and Africa markets in 2015, attributed to a lack of new product launches and insufficient marketing personnel [5] - Future marketing efforts will concentrate on the US market, with plans to enhance bidding qualifications for better market penetration [5]